Baay M F, Duk J M, Burger M P, Walboomers J, ter Schegget J, Groenier K H, de Bruijn H W, Stolz E, Herbrink P
Department of Dermatovenereology, Erasmus University, Rotterdam, The Netherlands.
J Clin Pathol. 1995 May;48(5):410-4. doi: 10.1136/jcp.48.5.410.
To investigate the correlation between antibodies to the transforming protein E7 of human papillomavirus (HPV) type 16 and clinicopathological indices in women with cervical squamous carcinoma.
A synthetic peptide of the HPV type 16 E7 protein (amino acids 6 to 35) was used to screen sera from 29 children, 130 women with cervical intraepithelial neoplasia, 443 women with cervical cancer, and 222 controls, for antibodies against this viral antigen. Bivariate and multivariate analyses were used to investigate the correlation between the serological status in the pretreatment sera and clinicopathological indices (size of the lesions, histological grade, stomal infiltration, vascular invasion, and nodal spread). Survival analysis was done using the Cox regression model for all FIGO stages and stages IB and ILA.
Cervical carcinoma patients had a significantly higher prevalence of antibodies to synthetic peptide E7/6-35 than women with cervical intraepithelial neoplasia (17.7% v 7%, p < 0.005) or controls (17.7% v 11%, p < 0.05). Bivariate analysis of the data on the presence of anti-E7/6-35 antibodies in the pretreatment sera from these patients and clinicopathological indices showed a significant correlation between the presence of anti-E7/6-35 antibodies and the size of the lesion (p = 0.0009), histological grade (p = 0.0031), and lymph node metastasis (p = 0.01). 0.011). In addition, the Cox regression model, analysing four risk factors which can be determined before treatment, showed a significant correlation between the presence of anti-E7/6-35 antibodies and a worse prognosis (p = 0.003). Survival analysis revealed that both for all FIGO stages (p = 0.0005) and for stages IB and IIA alone (p = 0.0021), anti-E7/6-35 positive patients before treatment had a significantly shorter life expectancy.
The presence of antibodies against E7/6-35 in pretreatment sera from patients with cervical carcinoma correlates with the size of the lesions, lymph node involvement, and a worse prognosis.
研究16型人乳头瘤病毒（HPV）转化蛋白E7抗体与宫颈鳞癌患者临床病理指标之间的相关性。
使用16型HPV E7蛋白（氨基酸6至35）的合成肽，筛查29名儿童、130名宫颈上皮内瘤变女性、443名宫颈癌女性及222名对照者血清中针对该病毒抗原的抗体。采用双变量和多变量分析，研究治疗前血清学状态与临床病理指标（病变大小、组织学分级、间质浸润、血管浸润和淋巴结转移）之间的相关性。使用Cox回归模型对所有国际妇产科联盟（FIGO）分期以及IB期和IIA期进行生存分析。
宫颈癌患者中针对合成肽E7/6 - 35的抗体阳性率显著高于宫颈上皮内瘤变女性（17.7%对7%，p < 0.005）或对照者（17.7%对11%，p < 0.05）。对这些患者治疗前血清中抗E7/6 - 35抗体的存在情况与临床病理指标数据进行双变量分析，结果显示抗E7/6 - 35抗体的存在与病变大小（p = 0.0009）、组织学分级（p = 0.0031）和淋巴结转移（p = 0.011）之间存在显著相关性。此外，Cox回归模型分析四个治疗前可确定的危险因素，结果显示抗E7/6 - 35抗体的存在与预后较差之间存在显著相关性（p = 0.003）。生存分析表明，对于所有FIGO分期（p = 0.0005）以及单独的IB期和IIA期（p = 0.0021），治疗前抗E7/6 - 35阳性患者的预期寿命显著缩短。
宫颈癌患者治疗前血清中抗E7/6 - 35抗体的存在与病变大小、淋巴结受累情况及预后较差相关。
